A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

被引：15
|
作者：
Gabrail, Nashat Y.
Hamilton, Erika P.
Elias, Anthony D.
Rimawi, Mothaffar F.
Li, Chao
Corvez, Maria Margarita
Li, Wei
Feng, Ying
Wei, Jiao
Greene, Stephanie
Patterson, John
Zeng, Qingping
Hui, Ai-Min
机构：
[1] Gabrail Canc Ctr Res LLC, Canton, OH USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA
[5] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
[6] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
[7] Orinove Inc, Newbury, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3080
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
    Rimawi, Mothaffar F.
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Marks, Douglas Kanter
    Elias, Anthony D.
    Pluard, Timothy J.
    Gabrail, Nashat Y.
    Patterson, John
    Greene, Stephanie
    Zeng, Qingping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors
    Li, Xiaoqing
    Bo, Yunhai
    Zeng, Qingping
    Diao, Lei
    Greene, Stephanie
    Patterson, John
    Liu, Lu
    Yang, Fen
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
    Dienstmann, R.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Rasco, D. W.
    Tabernero, J.
    Brana, I.
    Piera, A.
    Skartved, N. J.
    Aladdin, H.
    Petersen, J.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [5] Eganelisib, a First-in-Class PI3Kg Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
    Hong, David S.
    Postow, Michael
    Chmielowski, Bartosz
    Sullivan, Ryan
    Patnaik, Amita
    Cohen, Ezra E. W.
    Shapiro, Geoffrey
    Steuer, Conor
    Gutierrez, Martin
    Yeckes-Rodin, Heather
    Ilaria Jr, Robert
    O'Connell, Brenda
    Peng, Joanna
    Peng, Guangbin
    Zizlsperger, Nora
    Tolcher, Anthony
    Wolchok, Jedd D.
    CLINICAL CANCER RESEARCH, 2023, 29 (12) : 2210 - 2219
  • [6] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
    Razak, Albiruni R. A.
    Soerensen, Morten Mau
    Mahipal, Amit
    Shacham, Sharon
    Yau, Cindy Y. F.
    Lassen, Ulrik Niels
    McCauley, Dilara
    Cooksey, Jennifer
    Tan, David Shao Peng
    Saint-Martin, Jean-Richard
    Landesman, Yossi
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors
    LoRusso, P.
    Miller, K.
    Shields, A.
    Saito, K.
    Yoshida, K.
    Aoyama, T.
    Winkler, R.
    Benedetti, F.
    Lenz, H. J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S119 - S119
  • [8] Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.
    Chung, Vincent
    Jhaveri, Komal L.
    Von Hoff, Daniel D.
    Huang, Xin-Yun
    Garmey, Edward Graeme
    Zhang, Jillian
    Tsai, Frank Yung-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors
    Aoyama, T.
    Fasolo, A.
    Stathis, A.
    Sessa, C.
    Hollebecque, A.
    Soria, J. C.
    Pastorino, A.
    Sobrero, A. S. Alberto
    Van Laethem, J. L.
    Saito, K.
    Yoshidas, K.
    Winkler, R.
    Benedetti, F.
    Gianni, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S117 - S118
12345